Wuhan YZY Biopharma Co., Ltd.

HK$4.00As of Sun 8 Nov 2026, 12:00 UTC
HKEX:2496Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 3Y CAGR (35.73%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.36
PE TTM —
TSR TTM (42.94%)
Mkt cap HK$775.4M
ROIC (15.67%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.08
26.98%
72.55%
Buy 12|12|6|5|6
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.07
0.08
0.08
0.09
18.88%
11.92%
11.59%
21.34%
Revenue¥M
51.46
52.72
53.93
53.18
13.94%
11.32%
7.65%
8.01%
Peers (US$98.91M)
Cap (US$)
PE
140.4M
6.941x
134.3M
—
Capital
TTM
5Y
10Y
Leveragex
0.851
(0.056)
(0.056)
EBIT/Intx
7.536
0.063
0.067
Own earn%
(30.38)
(131.35)
(125.80)
Sh yield%
28.51
33.99
34.04
Owners
Insiders/Inst%
4.66
45.49
Short interest%
3.87
SBC / revenue%
3.42
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
31–42
$1 testx
—
Incr. ROIC%
5